Efficacy and Tolerance of URGO AWC_008 and URGO AWC_022 Dressings (EXPANSION)

Laboratoires URGO85 enrolled

Overview

Evaluation of the efficacy (wound epithelialization and time to closure) and tolerance (emergence and nature of adverse event) of the new URGO AWC\_008 and URGO AWC\_022 dressings in local management of acute and chronic wounds at risk of local infection or with clinical signs of local infection

prospective multicenter, non comparative clinical investigation This is a prospective multicenter, non comparative open-label, clinical investigation conducted in patients with acute and chronic wounds at risk of local infection or with clinical signs of local infection. This study is carried out in France and Spain in around 30 investigator sites. A total of 85 patients meeting the eligibility criteria will be included. The patients will be followed for 4 weeks and a total of 5 clinical evaluations will be carried out by the investigating centers. A planimetric survey of the studied wounds is carried out during the initial assessment of the wound (Day 0) and at each assessment provided for in the protocol (Week 1, Week 2, Week 3 and Week 4).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Foot Ulcer Venous Leg Ulcer Pressure Ulcer Wound Infection Acute Wounds

Interventions

URGO AWC_008 dressing or URGO AWC_022 dressingDEVICE

local management of acute or chronic wounds

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria : Related to all wounds : * Adult patient having given free, informed and written consent * Patient affiliated to a social security insurance scheme (applicable For France), * Inpatient or outpatient who can be followed by the same investigative team throughout the investigation, * Acute wound (burn, traumatic wound, unstitched surgical wound) or chronic wound (leg ulcer, pressure ulcer, diabetic foot ulcer), * Wound whose surface can be covered by a single dressing, * Wound at least 3 cm from any edge of another wound. Related to acute wounds, leg ulcer, pressure ulcer: Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 3 of the following clinical signs: * Pain (spontaneous, pressure pain or increased pain), * Peri-wound erythema, * Oedema, induration or swelling, * Odour (increase, change), * Exudate (colour modification or increase of exudate), * Local warmth, * Hypergranulation, * Bleeding, friable granulation tissue, * Stagnant healing/wound deterioration. Related to diabetic foot ulcer : Patient whose studied wound presents a risk of local infection (based on modified W.A.R. score ≥ 3 points) or with at least 2 of the following clinical signs: * Pain (spontaneous, pressure pain or increased pain), * Peri-wound erythema between 0.5-2.0 cm around the wound, * Oedema, induration or swelling, * Odour (increase, change), * Exudate (colour modification or increase of exudate), * Local warmth, * Hypergranulation, * Bleeding, friable granulation tissue, * Stagnant healing/wound deterioration, Exclusion Criteria: * Patient with a wound for which treatment in a hyperbaric chamber is planned within 4 weeks following inclusion, * Patient with a serious general condition, that could lead to withdrawal from the trial before four weeks of treatment, * Patient who has experienced an acute ischaemic event (acute myocardial infarction or stroke) during the 3 months prior to inclusion in the investigation, * Patient with a systemic infection * Wound totally or partially covered on its surface with a black plaque of necrosis, * Cancerous wound

Locations (1)

URGO

Dijon, France

RECRUITING

Outcomes

Primary Outcomes

relative wound area reduction (RWAR)

changes in the area of wounds after 4 weeks of treatment.

Time frame: 4 week treatment period

Secondary Outcomes

percentage of patients whose wound has healed

Complete closure of the Venous Leg Ulcer (VLU) - Healing of the wound is defined by 100% re-epithelialization of the wound

Time frame: 4 week treatment period

Nature and incidence of Treatment Adverse Effects as assessed in percentage for each dressing

Safety analysis with nature and number of adverse event related to the use of the dressings (serious/ non-serious)

Time frame: 4 week treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.